Everything below concerns Albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Hydroxyapatite (IMA name: hydroxylapatite) (Hap, HAp, or HA) is a naturally occurring mineral form of apatite with the formula Ca5(PO4)3(OH), often written Ca10(PO4)6(OH)2 to denote that the crystal unit cell comprises two entities. It is the hydroxyl endmember of the complex apatite group. The OH− ion can be replaced by fluoride or chloride, producing fluorapatite or chlorapatite. It crystallizes in the hexagonal crystal system. Pure hydroxyapatite powder is white. Naturally occurring apatites can, however, also have brown, yellow, or green colorations, comparable to the discolorations of dental fluorosis. Up to 50% by volume and 70% by weight of human bone is a modified form of hydroxyapatite, known as bone mineral. Carbonated calcium-deficient hydroxyapatite is the main mineral of which dental enamel and dentin are composed. Hydroxyapatite crystals are also found in pathological calcifications such as those found in breast tumors, as well as calcifications within the pineal gland (and other structures of the brain) known as corpora arenacea or "brain sand".
In separation, the selfish subsystem grew faster than the cooperative one. After mixing selfish ribozymes with cooperative ones, the emergence of cooperative behaviour in a merged population was observed, outperforming the self-assembling subsystems. Moreover, the selfish ribozymes were integrated into the network of reactions, supporting its growth. These results were also explained analytically by the ODE model and its analysis. They differ substantially from results obtained in evolutionary dynamics. According to evolutionary dynamics theory, selfish molecules should dominate the system even if the growth rate of the selfish subsystem in isolation is lower than the growth rate of the cooperative system. Moreover, Vaidya et al. proved that, when fragmented into more pieces, ribozymes that are capable of self-assembly can not only still form catalytic cycles but, indeed, favour them. Results obtained from experiments by Vaidya et al. gave a glimpse on how inefficient prebiotic polymerases, capable of synthesizing only short oligomers, could be sufficient at the pre-life stage to spark off life. This could happen because coupling the synthesis of short RNA fragments by the first ribozymal polymerases to a system capable of self-assembly not only enables building longer sequences but also allows exploiting the fitness space more efficiently with the use of the recombination process. Another experiment performed by Hannes Mutschler et al.
where j is the James–Martin pressure drop correction, m is the sample mass, F is the carrier gas flow rate at standard temperature and pressure, tR is the gross retention time for the injected probe, to is the retention time for a non-interaction probe (i.e. dead-time), and T is the absolute temperature.
Sources: en.wikipedia.org
== Taxonomy == French botanist François Alexandre Pierre de Garsault described the species as Balanus myrepsica, but his names are not accepted as valid, as he did not always give his descriptions binomial names. French naturalist Jean-Baptiste Lamarck described the species in 1785. A combined analysis of morphology and DNA shows that M. oleifera is most closely related to M. concanensis, and the common ancestor of these two diverged from the lineage of M. peregrina.
=== Vitamin B12 structure === In 1948, Hodgkin first encountered vitamin B12, one of the most structurally complex vitamins known, and created new crystals. Vitamin B12 had first been discovered at Merck earlier that year. It had a structure at the time that was almost completely unknown, and when Hodgkin discovered it contained cobalt, she realized the structure actualization could be determined by X-ray crystallography analysis. The large size of the molecule, and the fact that the atoms were largely unaccounted for—aside from cobalt—posed a challenge in structure analysis that had not been previously explored. From these crystals, she deduced the presence of a ring structure because the crystals were pleochroic, a finding which she later confirmed using X-ray crystallography. The B12 study published by Hodgkin was described by Lawrence Bragg as being as significant "as breaking the sound barrier". Scientists from Merck had previously crystallised B12, but had published only refractive indices of the substance. The final structure of B12, for which Hodgkin was later awarded the Nobel Prize, was published in 1955 and 1956.
1st Airborne Battle Group (ABG), 187th Infantry (reassigned from the 24th Infantry Division on 8 February 1959)(1) 1st ABG, 325th Infantry 2nd ABG, 501st Infantry 1st ABG, 503d Infantry (reassigned from the 24th Infantry Division on 1 July 1958)(2) 2nd ABG, 503rd Infantry (reassigned to the 25th Infantry Division on 24 June 1960) 1st ABG, 504th Infantry (reassigned to the 8th Infantry Division on 11 December 1958) 2nd ABG, 504th Infantry (assigned effective 9 May 1960)(1) 1st ABG, 505th Infantry (reassigned to the 8th Infantry Division on 15 January 1959) (1) 1st ABG, 504th Infantry and 1st ABG, 505th Infantry were reassigned to the 8th Infantry Division in central West Germany to provide airborne capability in Germany; in turn, 1–187th and 1-503d were reassigned from the 24th Infantry Division in southern Germany to the 82nd Airborne Division (2) 2nd ABG, 503rd Infantry was reassigned to the 25th Infantry Division and stationed in Okinawa to provide airborne capability in the Pacific on 24 June 1960. This ABG was reassigned to the 173d Airborne Brigade on 26 March 1963.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.